Jco precision oncology.
Pancreatic cancer remains one of the leading causes of cancer-related death, with an estimated 64,050 new cases and 50,550 deaths in the United States in 2023. 1 Among various malignancies, pancreatic cancer is considered highly aggressive and exhibits one of the lowest 5-year survival rates at 10%. 1 Pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 90% of cases of pancreatic ...
PURPOSE Precision medicine uses advanced molecular techniques to guide the use of targeted therapeutic drugs and is an emerging paradigm in pediatric oncology. Clinical evidence related to the efficacy of many novel targeted drugs, however, is currently very limited given the rarity of pediatric cancer and the lack of published evidence for the …DOI: 10.1200/PO.22.00258 JCO Precision Oncology no. 7 (2023) e2200258. Published online January 30, 2023. PMID: 36716415. Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial Eric Pujade-Lauraine, MD 1. x. …JCO PO is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics- and other biomarker-driven clinical care of patients with cancer. Innovative and timely scientific and educational content provide a deeper ...OncoKB, a comprehensive and curated precision oncology knowledge base, offers oncologists detailed, evidence-based information about individual somatic mutations and structural alterations present in patient tumors with …Web
Although precision oncology is transforming clinical management of patients with cancer, many hospitals face challenges to effectively implement precision oncology. In addition, the cost and time exerted for genomic profiling needs to be balanced with expectations of benefit for each patient. This article summarizes the effort to …WebDOI: 10.1200/PO.19.00154 JCO Precision Oncology no. 4 (2020) 6-19. Published online January 7, 2020. PMID: 35050726. International Harmonization of Provisional Diagnostic Criteria for ...By choosing this option you are agreeing to pay the article processing charge of $2,300 (Original Reports) or $792 (Case Reports). This will be billed after acceptance of your article. Open access requirements may vary depending on the source of funding for your submission. If you have questions regarding open access requirements, this guide to ...
詳細. タイトル. JCO precision oncology. JCO precision oncology. ... American Society of Clinical Oncology, publisher. ... Began with February 22, 2017. Began with ...
DOI: 10.1200/PO.21.00011 JCO Precision Oncology no. 5 (2021) 1687-1698. Published online November 3, 2021. Published online November 3, 2021. Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown PrimaryDOI: 10.1200/PO.18.00325 JCO Precision Oncology - published online June 13, 2019DOI: 10.1200/PO.22.00694 JCO Precision Oncology no. 7 (2023) e2200694. Published online September 1, 2023. PMID: 37656949. Dynamic Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer Milena Urbini, PhD 1. x. Milena Urbini. Search for articles by this author ...From Race-Based to Precision Oncology: Leveraging Behavioral Economics and the Electronic Health Record to Advance Health Equity in Cancer Care Lau-Min et al. Published online: February 17, 2021May 3, 2021 · DOI: 10.1200/PO.20.00534 JCO Precision Oncology no. 5 (2021) 771-778. Published online May 3, 2021. Published online May 3, 2021. Clinical Responses to Crizotinib, Alectinib, and Lorlatinib in a Metastatic Colorectal Carcinoma Patient With ALK Gene Rearrangement: A Case Report
PURPOSE The STAMPEDE trial recruits men with newly diagnosed, high-risk, hormone-sensitive prostate cancer. To ascertain the feasibility of targeted next-generation sequencing (tNGS) and the prevalence of baseline genomic aberrations, we sequenced tumor and germline DNA from patients with metastatic prostate cancer (mPCa) starting long-term androgen-deprivation therapy (ADT). METHODS In a 2 ...
As described in a study in JCO Precision Oncology, Sadik et al. conducted a thorough analysis of factors impacting systematic operational integration of biomarker testing for targeted therapy in ...
PURPOSE Hyperthermic intraperitoneal chemotherapy (HIPEC) confers a survival benefit in epithelial ovarian cancer (EOC) and in preclinical models. However, the molecular changes induced by HIPEC have not been corroborated in humans. PATIENTS AND METHODS A feasibility trial evaluated clinical and safety outcomes of HIPEC with cisplatin during optimal cytoreductive surgery (CRS) in patients with ...DOI: 10.1200/PO.22.00580 JCO Precision Oncology no. 7 (2023) e2200580. Published online March 23, 2023. PMID: 36952646. Polygenic Pharmacogenomic Markers as Predictors of Toxicity Phenotypes in the Treatment of Acute Lymphoblastic Leukemia: A Single-Center Study Trisha Larkin, MD 1, 2. x. Trisha Larkin. …WebDOI: 10.1200/PO.19.00032 JCO Precision Oncology - published online October 24, 2019PURPOSE CATCH (Comprehensive Assessment of clinical feaTures and biomarkers to identify patients with advanced or metastatic breast Cancer for marker driven trials in Humans) is a prospective precision oncology program that uses genomics and transcriptomics to guide therapeutic decisions in the clinical management of metastatic breast cancer. Herein, we report our single-center experience and ...Notable Labs Announces JCO Precision Oncology Publication Demonstrating PPMP… ... EACH PATIENT IS NOTABLE AND CAN BENEFIT FROM A PREDICTIVE PRECISION MEDICINE ...
DOI: 10.1200/PO.21.00535 JCO Precision Oncology no. 6 (2022) e2100535. Published online May 11, 2022. PMID: 35544728. Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer Hideaki Bando, MD 1, 2. x. Hideaki Bando. Search for articles by this author ...WebJCO Precis Oncol. 2017; 1: ... To address these limitations, we describe OncoKB, a comprehensive precision oncology knowledge base that offers oncologists detailed, evidence-based information about individual somatic mutations and structural alterations present in patient tumors to support optimal treatment decisions. OncoKB …DOI: 10.1200/PO.19.00172 JCO Precision Oncology - published online September 20, 2019 PMID: 32923866. Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia Roberta La Starza, MD, PhD 1. x. Roberta La Starza. Search for articles by this author ...Key Objective. To improve identification of hereditary cancer syndromes in individuals with colorectal cancer (CRC), a statewide initiative was created to provide universal tumor screening for Lynch syndrome (LS) for 3,310 unselected patients with CRC (the largest cohort to date) and to provide germline pan-cancer multigene panel testing to selected patients with CRC to assess frequency and ... Limit abstract length to 275 words. Limit body text to 3,000 words (excluding the title page, abstract, references, figures, and tables). Limit of 6 total figures and tables, not including figure pieces. Table pieces (such as Table 1a and 1b) are not allowed. Include a CONSORT diagram for studies in which two or more groups are compared.
DOI: 10.1200/PO.20.00525 JCO Precision Oncology no. 5 (2021) 779-791. Published online May 5, 2021. Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative Rachel Pearlman, MS 1. x. Rachel Pearlman. Search for articles by this author ...
DOI: 10.1200/PO.20.00257 JCO Precision Oncology no. 4 (2020) 1393-1402. Published online November 16, 2020. Published online November 16, 2020. BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted TherapiesPURPOSE We conducted this systematic review to evaluate the clinical outcomes associated with molecular tumor board (MTB) review in patients with cancer. METHODS A systematic search of PubMed was performed to identify studies reporting clinical outcomes in patients with cancer who were reviewed by an MTB. To be included, studies had to report clinical outcomes, including clinical benefit ...OncoKB, a comprehensive and curated precision oncology knowledge base, offers oncologists detailed, evidence-based information about individual somatic mutations and structural alterations present in patient tumors with the goal of supporting optimal treatment decisions.DOI: 10.1200/PO.22.00363 JCO Precision Oncology no. 7 (2023) e2200363. Published online May 24, 2023. PMID: 37224427. Exceptional Response to Dual Colony-Stimulating Factor 1 Receptor/PD-L1 Targeting After Primary Resistance to PD-1 Inhibition in a Patient With a Metastatic Uveal Melanoma ...DOI: 10.1200/PO.20.00178 JCO Precision Oncology no. 5 (2021) 44-50. Published online January 8, 2021. Published online January 8, 2021. Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 AlterationsOncoKB, a comprehensive and curated precision oncology knowledge base, offers oncologists detailed, evidence-based information about individual somatic mutations …DOI: 10.1200/PO.19.00124 JCO Precision Oncology - published online August 14, 2019Precision oncology relies on robust molecular analyses of patient samples and accurate interpretation of genomic sequencing and biomarker data. 1 Advances in genomic sequencing have made tumor genomic profiling a routine process in the clinical evaluation and treatment planning of patients with cancer. 2 The main objective is to provide a detailed characterization of a patient's neoplasm ...DOI: 10.1200/PO.20.00438 JCO Precision Oncology no. 5 (2021) 1659-1665. Published online October 27, 2021. Clinical Utility of Functional Precision Medicine in the Management of Recurrent/Relapsed Childhood Rhabdomyosarcoma Arlet M. Acanda De La Rocha, PhD 1. x. Arlet M. Acanda De La Rocha. Search for articles by this author ...
Jan 27, 2022 · This author is an Associate Editor for JCO Precision Oncology. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: Ciitizen Corporation, Clariifi, Guidance Genomics. Consulting or Advisory Role: Roche, Roche/Genentech. Speakers' Bureau: Genentech
JCO PO is a peerreviewed onlineonly articlebased journal publishing original research reports opinions and reviews that advance the science and practice of precision oncology and define genomics and other biomarkerdriven clinical care of patients with cancer. Innovative and timely scientific and educational content provide a deeper ...
Limit the abstract to 275 words and place it after the title page. Do not use proprietary or trade names in the title or abstract. Case Reports, Commentaries, Editorials, and Correspondence articles do not require abstracts. Write the body of the manuscript as concisely as possible.Lung cancer is the leading cause of cancer-related death worldwide. Non–small-cell lung cancer (NSCLC), which accounts for 85% of all lung cancer cases, 1 is a group of heterogeneous diseases driven by a spectrum of molecular alterations. Targeted therapies directed toward specific molecular alterations, such as a mutation in epidermal …詳細. タイトル. JCO precision oncology. JCO precision oncology. ... American Society of Clinical Oncology, publisher. ... Began with February 22, 2017. Began with ...DOI: 10.1200/PO.22.00531 JCO Precision Oncology no. 7 (2023) e2200531. Published online May 4, 2023. PMID: 37141549. Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis Lorenzo Gerratana, MD 1. x. Lorenzo Gerratana. Search for articles by this …Initiative for Molecular Profiling and. Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. JCO Precis. Oncol 2017;2017.. [5] Le Tourneau ...6 Oct 2022 ... Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board. JCO Precis Oncol 2017, PO.JCO PO is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision …DOI: 10.1200/PO.21.00437 JCO Precision Oncology no. 6 (2022) e2100437. Published online January 27, 2022. Published online January 27, 2022. Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature …Stage 4 is the final stage of most cancers that have spread to other areas of the body, states the American Society of Clinical Oncology. Cancer stages are usually determined by the size, growth and spread of the cancer.Feb 16, 2022 · The actual frequency of NTRK fusions in thyroid cancer is not known, as some targeted exome sequencing can easily miss fusion event involving introns of certain genes. Studies on frequency of NTRK fusions from a single institution and from the TCGA found NTRK fusion in 10 of 451 (2.2%; four NTRK1 and six NTRK3 fusions) and 12 of 498 (2.4%; five ... 6 Nov 2023 ... jpg. Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer ...
DOI: 10.1200/PO.18.00037 JCO Precision Oncology - published online July 23, 2018WebPURPOSE In the two-cohort phase II KEYNOTE-086 study (ClinicalTrials.gov identifier: NCT02447003), first-line and second-line or later pembrolizumab monotherapy demonstrated antitumor activity in metastatic triple-negative breast cancer (mTNBC; N = 254). This exploratory analysis evaluates the association between prespecified molecular biomarkers and clinical outcomes. METHODS Cohort A ...DOI: 10.1200/PO.20.00417 JCO Precision Oncology no. 5 (2021) 450-454. Published online February 26, 2021. PMID: 34994601. NTRK Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets Elke Pfaff, MD. x. Elke Pfaff. Search for articles by this author ...DOI: 10.1200/PO.20.00325 JCO Precision Oncology no. 5 (2021) 442-449. Published online February 24, 2021. Published online February 24, 2021. GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer–Specific MortalityInstagram:https://instagram. is sdiv a good investment2021 quarters worth moneystocks to buy for 2023banzinga pro OncoKB, a comprehensive and curated precision oncology knowledge base, offers oncologists detailed, evidence-based information about individual somatic mutations and structural alterations present in patient tumors with the goal of supporting optimal treatment decisions. blue chip dividendnyse bdx As significant efforts in distinct geographical areas are underway to enhance the clinical impact of precision oncology, several challenges remain. First, the type of tumor sample used can affect the results of genomic assays and have downstream effects on therapeutic decisions. In a study comparing mutation calls from whole-exome sequencing in ... llc naming ideas 29 Sept 2022 ... Precision medicine in pediatric oncology. ... Improved gene fusion detection in childhood cancer diagnostics using RNA sequencing. JCO Precis ...DOI: 10.1200/PO.22.00509 JCO Precision Oncology no. 7 (2023) e2200509. Published online April 7, 2023. PMID: 37027812. Tumor-Naïve Circulating Tumor DNA as an Early Response Biomarker for Patients Treated With Immunotherapy in Early Phase Clinical Trials Enrique Sanz-Garcia, MD, PhD 1. x. Enrique Sanz-Garcia. Search for articles by …Web